Limited Edition Golden Llama is here! Check out how you can get one. 
Limited Edition Golden Llama is here! Check out how you can get one.
Offering SPR-BLI Services - Proteins provided for free! Offering SPR-BLI Services - Proteins provided for free!
Thank you for choosing ACROBiosystems. Would you rate our product and service？ Thank you for choosing ACROBiosystems. Would you rate our product and service？
Here come GMP Grade Cytokines！Free Sample is available！ Here come GMP Grade Cytokines！Free Sample is available！
| 製造番号 | 種類 | 製品説明 | 構造 | 純度 | 特徴 |
|---|---|---|---|---|---|
| CD6-R52H9 | Rat | Rat B7-2 / CD86 Protein, His Tag |  |
|
|
| CD6-H82F5 | Human | Biotinylated Human B7-2 / CD86 Protein, Fc,Avitag™, premium grade |  |
|
|
| CD6-M52H0 | Mouse | Mouse B7-2 / CD86 Protein, His Tag (MALS verified) |  |
|
|
| CD6-M5251 | Mouse | Mouse B7-2 / CD86 Protein, Fc Tag (MALS verified) |  |
|
|
| CD6-C5254 | Cynomolgus / Rhesus macaque | Cynomolgus / Rhesus macaque B7-2 / CD86 Protein, Fc Tag |  |
|
|
| CD6-C52H5 | Cynomolgus / Rhesus macaque | Cynomolgus / Rhesus macaque B7-2 / CD86 Protein, His Tag (MALS verified) |  |
|
|
| CD6-H5223 | Human | Human B7-2 / CD86 Protein, His Tag (MALS verified) |  |
|
|
| CD6-H5257 | Human | Human B7-2 / CD86 Protein, Fc Tag, premium grade |  |
|
Flow Cytometry assay shows that Biotinylated Human B7-2, Fc,Avitag, premium grade (Cat. No. CD6-H82F5) can bind to CD28 expressed on Jurkat E6.1 cells. The concentration of B7-2 used is 1.5 μg/mL (Routinely tested).
FACS analysis shows that the binding of Biotinylated Human B7-2, Fc,Avitag, premium grade (Cat. No. CD6-H82F5) to CD28 expressed on Jurkat E6.1 was inhibited by increasing concentration of neutralizing Anti-CD28 antibody. The concentration of B7-2 used is 1.5 μg/mL. The IC50 is 0.031 μg/mL (Routinely tested).
Loaded Cynomolgus / Rhesus macaque B7-2, Fc Tag (Cat. No. CD6-C5254) on Protein A Biosensor, can bind Human / Cynomolgus / Rhesus macaque CD28, His Tag with an affinity constant of 11 μM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).
| Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
|---|---|---|---|---|---|---|---|---|---|---|
| Belatacept | LEA29Y; LEA-029; BMS-224818; L104EA29YIg | Approved | Bristol-Myers Squibb Company | Nulojix | EU | Rejection of renal transplantation | Bristol-Myers Squibb Pharma Eeig | 2011-06-15 | Rejection of renal transplantation; Diabetes Mellitus, Type 1; Arthritis, Rheumatoid; Pancreatic neuroendocrine tumors (pNET); Proteinuria; Rejection of organ transplantation; Delayed Graft Function; Rejection in heart transplantation; Kidney Failure, Chronic | Details |
| Abatacept | ONO-4164; BMS-188667; BMS-188667SC; ONO-4164SC | Approved | Bristol-Myers Squibb Company | Orencia | United States | Graft vs Host Disease | Bristol Myers Squibb Srlcompany | 2005-12-23 | Arthritis, Psoriatic; Arthritis; Arthralgia; Common Variable Immunodeficiency; Cardiovascular Diseases; Sjogren-Larsson Syndrome; Urticaria; Asthma; Colitis, Ulcerative; Nephrotic Syndrome; Lupus Erythematosus, Systemic; Takayasu Arteritis; Psoriasis; Anemia, Aplastic; Glomerulosclerosis, Focal Segmental; Mucopolysaccharidosis I; Polymyalgia Rheumatica; Multiple Sclerosis; Leukocyte-Adhesion Deficiency Syndrome; Uveitis; Granulomatous Disease, Chronic; Lymphohistiocytosis, Hemophagocytic; Scleroderma, Diffuse; Inflammation; Myocarditis; Eye Diseases; Muscular Diseases; Crohn Disease; Behcet Syndrome; Kostmann Syndrome; Anemia, Sickle Cell; Thrombasthenia; Vitiligo; Spondylitis, Ankylosing; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Myasthenia Gravis; Granulomatosis with Polyangiitis; Wiskott-Aldrich Syndrome; Polymyositis; Diabetes Mellitus, Type 1; Multiple Sclerosis, Relapsing-Remitting; Hematologic Diseases; Alopecia Areata; Giant Cell Arteritis; Myositis; Dermatomyositis; Immunoglobulin G | Details |
| Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
|---|---|---|---|---|---|
| CTLA-4/FasL fusion protein (KAHR Medical) | KAHR-102 | Kahr Medical | Details | ||
| Chimeric antigen receptor T-cell therapy (Hunan Zhaotai Yongren Biotech) | Z-CTLs | Phase 1 Clinical | Hunan Zhaotai Yongren Biotech Co Ltd | Carcinoma, Non-Small-Cell Lung | Details |
| Recombinant human CTLA-4-FC fusion protein(Beijing Vdjbio) | Phase 1 Clinical | Beijing Vdjbio Co Ltd | Arthritis, Rheumatoid | Details | |
| ORCA-010 | ORCA-010 | Phase 2 Clinical | Orca Therapeutics Bv | Prostatic Neoplasms | Details |
This web search service is supported by Google Inc.
アクロバイオシステムズの公式アカウント
A-Z
